By CNBC |
December 02, 2019
Biogen’s stock could fall as much as 10% once it releases new data this week on its Alzheimer’s drug, analyst Brian Skorney says. “We do not think that data validates anything near receiving approval from the FDA,” he adds.
Recent research on Paxlovid shows there is "solid data on its effectiveness," a co-author of the study told HealthLeaders.
One of the most important elements of a company’s success is also one of the least tangible —culture.